Tag: TACE

ablation

Ablation cheaper than Y-90 or TACE for the treatment of hepatocellular...

Ablation costs are significantly less than those of transarterial chemoembolization (TACE) and Yttrium-90 (Y-90), according to a comparative cost analysis of the three...
TACE

ET 2019: New data support TACE using microspheres in both HCC...

Transarterial chemoembolization using microspheres appears to show “much better outcomes” than those seen with conventional TACE, both in the setting of hepatocellular carcinoma (HCC)...

Artificial intelligence will support clinical decision making in interventional oncology

Aaron Abajian and Julius Chapiro, New Haven, USA, write about results from an early experiment in applying artificial intelligence (AI) and machine learning as a...

New data demonstrate clinical experience with LifePearl microspheres in over 300...

Transarterial chemoembolization (TACE) using LifePearl (Terumo) drug-eluting embolic agents in the treatment of hepatocellular carcinoma has just been published.

International survey reveals high variability in TACE technique

Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...
randomised

Radiation segmentectomy offers new treatment option for liver cancer

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

First patient enrolled in CIREL, a Europe-wide observational study on TACE...

The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) announced that the first patient has been enrolled in CIREL (CIRSE registry for LifePearl microspheres),...

Terumo Europe NV announces approval of LifePearl as a Class III...

This approval also expands the number of chemotherapeutic drugs that can be loaded onto LifePearl to include idarubicin and epirubicin, a press release from...

Vast majority of patients prefer radial access for embolization therapies in...

“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the...

Mentice aims to reduce TACE procedure times and radiation exposure with...

Mentice has announced the release of a new simulation training software for transarterial chemoembolization (TACE). The new software was showcased at the 2017 CIRSE...
ablation

Dexamethasone treatment prevents TACE side-effects in hepatocellular carcinoma patients

A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in...

CIRSE launches Europe-wide study of transarterial chemoembolization with Terumo Lifepearl

  The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for LifePearl Microspheres (CIREL), a new European-wide observational study that...

Thailand FDA approves new indication for Guerbet’s Lipiodol Ultra-Fluide

Guerbet has announced that the Thailand FDA has given approval of a new indication for Lipiodol Ultra-Fluide for selective hepatic intra-arterial injection for visualisation,...

Surefire closes US$12.8 million funding, to present new data at SIR

Surefire, the developer of site-specific delivery devices for the interventional oncology market, has announced the first closing of a US$12.8 M Series D financing...

Canada first country to get DC Bead Lumi treatment for liver...

BTG International Canada has announced the commercial launch of DC Bead Lumi in Canada. The launch represents the first market commercialisation of DC Bead...